ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?-Reference-Cited by-同舟云学术

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Published:2014-11-21 Issue:2 Volume:15 Page:225-233
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Girard Nicolas,Audigier-Valette Clarisse,Cortot Alexis B,Mennecier Bertrand,Debieuvre Didier,Planchard David,Zalcman Gérard,Moro-Sibilot Denis,Cadranel Jacques,Barlési Fabrice

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2014.986103

Reference28 articles.

1. New driver mutations in non-small-cell lung cancer

2. Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

3. Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

4. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials;Expert Opinion on Drug Safety;2023-02-26

2. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively;Diagnostic Pathology;2022-02-10

3. An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model;Frontiers in Oncology;2022-01-28

4. Anaplastic lymphoma kinase tyrosine kinase inhibitor‐induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database;Journal of Clinical Pharmacy and Therapeutics;2021-03-25

5. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians;Critical Reviews in Oncology/Hematology;2021-01